Gastrointestinal Cancer

Benjamin Leon Musher, MD, discusses the current treatment options for patients with hepatocellular carcinoma.

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine and committee vice chair at The University of Texas MD Anderson Cancer Center, discusses investigational targeted therapies in metastatic colorectal cancer (mCRC).

Matthew H.G. Katz, MD, FACS, discusses data with neoadjuvant therapy and ongoing research in pancreatic cancer.

Kanwal Raghav, MBBS, MD, discusses the implications of molecular profiling on treatment decisions in metastatic colorectal cancer and the importance of referring patients to clinical trials.

Shubham Pant, MD, discusses combination immunotherapies and upcoming developments in pancreatic cancer.

Ahmed O. Kaseb, MD, discusses important considerations in the frontline treatment of patients with advanced hepatocellular carcinoma, the potential for targeted therapy in the space, and ongoing research with immunotherapy in earlier stages of disease.

Benjamin Leon Musher, MD, discusses sequencing challenges and research efforts needed regarding immunotherapy in hepatocellular carcinoma before it becomes a standard approach for patients.

We recently traveled to Brooklyn, New York, for a State of the Science Summit™ on Gastrointestinal Cancer, which featured insights from Weill Cornell Medical Center and Montefiore Medical Center faculty.

Michael R. Charlton, MD, MBBS, discusses the emergence of biomarkers in hepatocellular carcinoma.

Michael J. Overman, MD, discusses the current treatment landscape of metastatic colorectal cancer and ongoing research efforts in the space.

The FDA has granted a breakthrough device designation to the Elecsys GALAD score, an algorithmic score designed to aid in the diagnosis of early-stage hepatocellular carcinoma.

Amir Khan, MD, discusses a large retrospective database analysis on colorectal cancer and gastric cancer presented at the 2020 Gastrointestinal Cancers Symposium.

Matthew H.G. Katz, MD, FACS, discusses the utility of preoperative chemotherapy for patients with resectable pancreatic cancer.

Dana-Farber Cancer Institute launched the Young-Onset Colorectal Cancer Center, among the first of its kind, in March 2019 to provide expert and compassionate clinical care, promote scientific discovery and innovation to elucidate underlying biological mechanisms, identify risk factors, and facilitate development of novel therapies, and improve prevention and early detection by raising public awareness of the rising burden of CRC in young adults.

There are clear biomarkers available to guide treatment decisions in the second-line setting for patients with advanced hepatocellular carcinoma, Lipika Goyal, MD, Mphil, said during a presentation at the 2020 HCC-TAG Conference.

Vincent Chung, MD, discusses the effect of gemcitabine, nab-paclitaxel (Abraxane), metformin, and dietary supplements on patients with pancreatic cancer.

Kanwal Raghav, MBBS, MD, discusses the activation of the RAS/RAF/MET/ERK pathway in colorectal cancer.

By 2025, Anthony El-Khoueiry, MD, expects to see a larger menu of approved drugs and drug combinations for the treatment of advanced hepatocellular carcinoma, better use of molecular and immune signatures to guide treatment decisions, and, possibly, the chance to cure intermediate- and advanced-stage disease.

Michael R. Charlton, MD, MBBS, discusses the evolution of hepatocellular carcinoma treatment.

Although the development of chemotherapy-free regimens is a major thrust of oncology research, improvements to traditional cytotoxic therapy are actively being explored, with a focus on new formulations and delivery methods for agents that have been used for decades.

Riad Salem, MD, discusses the utility of locoregional therapy versus systemic therapy in the treatment of patients with hepatocellular carcinoma.

Amit G. Singal, MD, discusses the importance of early diagnosis for patients with hepatocellular carcinoma.

Following a series of negative phase III single-agent trials in hepatocellular carcinoma, investigators are finding better results with immunotherapy combination regimens.

Clinical evidence shows that patients with hepatocellular carcinoma who receive care that incorporates multiple providers from a variety disciplines leads to better results.

Anjana Pillai, MD, reflects on the first annual HCC-TAG Conference, her journey into treating patients with liver cancer, and remaining challenges in the paradigm